[go: up one dir, main page]

EP0082877A1 - Preparation d'erythrocytes synthetiques - Google Patents

Preparation d'erythrocytes synthetiques

Info

Publication number
EP0082877A1
EP0082877A1 EP82902427A EP82902427A EP0082877A1 EP 0082877 A1 EP0082877 A1 EP 0082877A1 EP 82902427 A EP82902427 A EP 82902427A EP 82902427 A EP82902427 A EP 82902427A EP 0082877 A1 EP0082877 A1 EP 0082877A1
Authority
EP
European Patent Office
Prior art keywords
preparation
erythrocytes
synthetic
stroma
hemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP82902427A
Other languages
German (de)
English (en)
Inventor
Ljubomir Djordjevich
Anthony Dragan Ivankovich
William Gottschalk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush Presbyterian St Lukes Medical Center
Original Assignee
Rush Presbyterian St Lukes Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush Presbyterian St Lukes Medical Center filed Critical Rush Presbyterian St Lukes Medical Center
Publication of EP0082877A1 publication Critical patent/EP0082877A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Definitions

  • Erythrocytes are the red blood cells of blood which serve the biological function of carrying oxygen to body tissues. In nature, the walls of the cells are membranes which contain many different kinds of proteins. Oxygen passes through these erythrocyte walls and is exchanged for carbon dioxide which the erythrocytfes carry away from the tissues.
  • O ne difficulty is that the natural erythrocytes in the blood of animals and humans deteriorate relatively soon after the blood is drawn, and present regulations require that the blood must be used for transfusion within 21 days after it is drawn.
  • Another serious inconvenience is that the blood of the donor must b e typed and transfusions made into subjects whose bl oo d is of the same type as that of the donor. Both of these disadvantages are due to the presence of the proteins which are contained within the membranes of the natural erythrocytes.
  • U. S . Patent No. 4,133,874 discloses a process in which a lipid in an organic solvent is spun to form a film on the interior walls of * a container and this film allowed to dry.
  • Stroma-free hemoglobin is added and by the use of ultra sound, hemoglobin is encapsulated within lipid membranes to form synthetic erythrocytes.
  • a principal object of the present invention is to discover improved methods by which synthetic erythrocytes may be produced effectively and efficiently an d in quantities sufficient to supply medical needs.
  • a further object is to discover processes for the encapsulation of stroma-free hemoglobin within
  • Another object is to discover processes which avoid waste of hemoglobin and produce a maximum quantity of synthetic erythrocytes from a given quantity of natural red blood cells.
  • Yet another object is to discover processes for treating or modifying the synthetic erythrocytes to preserve them in a viable state for extended periods of time.
  • stromafree hemoglobin from mammalian blood, combine this with a phospholipid composition, and pass this combination under pressure through an orifice to thereby encapsulate stroma-free hemoglobin within membranes of the phospholipid compositions so as to produce synthetic erythrocytes which, being free of the proteins contained in natural erythrocytes, remain useful over a much longer period than do the natural erythrocytes.
  • the interaction between the hemoglobin and the lipid is not limited to the surface of a lipid film on the interior of a container as was the case in the process described in Patent No. 4,133,874.
  • Fig. 1 is a schematic flow diagram of our process
  • Fig. 2 is a view in cross section of one type of orifice which may be used to produce encapsulation of the stroma-free hemoglobin within phospholipid membranes;
  • Fig. 3 is a view in cross section of another type of orifice which may be used and
  • Fig. 4 is a sectional view of yet another type of orifice which may be used in the practice of the invention.
  • Fig. 1 squares or blocks are used to represent steps or units of equipment.
  • the character 10 designates a container for a saline solution. Saline solution is passed through a centrifuge 11 used to separate plasma from whole blood. The blood may have been drawn from humans or from other mammals. The plasma is separated off, and the fraction containing the red blood cells, or erythrocytes, is passed to step 12 where the natural erythrocytes are subjected to alternate freezing and thawing to rupture the membranes of any remaining cells, after which the membranes and any tissue is removed by filtration, leaving stroma-free hemoglobin. The stroma-free hemoglobin may be held in the receptable 13.
  • a mixing vessel 14 into which a quantity of a phospholipid is fed from a container 15.
  • a container 15 This may be any kind of phospholipid, preferably lecithin.
  • a sterol such as cholesterol from container 16
  • dicetyl phosphate may be added from container 17 to give the mixture the desired electrical charge.
  • An organic solvent may be added from the container 18. The phospholipid and other added ingredients are mixed, using mixer 19, and t mixture fed into the pressure vessel 20.
  • a mixing device 20a Associated with the pressure vessel 20 is a mixing device 20a, a*/ vacuum pump 22 by the which the solvent may be evaporated and drawn off from this vessel, and a high pressure pump 23 capable of developing a pressure of at least 500 pounds per square inch and preferable at least 1500 pounds per square inch.
  • the pump be capable of producing pressures as high as can practicably be reached up to pressures of the order of 10,000 pounds per square inch.
  • the vacuum pump 22 may be activated to evaporate and draw off the organic solvent.
  • the stroma-free hemoglobin from receptable 13 may be introduced into the vessel 20 and the mixer 20a operated to bring the ingredients within this vessel into a * homogeneous mass.
  • the vessel 20 has means 35 for heating vessel 20 to maintain a temperature of about 35-40°C.
  • an orifice 25 which may be of the type illustrated in either of Fig. 1, Fig. 2, or Fig. 3.
  • the type illustrated in Fig. 1 is the ordinary orifice in the wall of a vessel.
  • the type shown in Fig. 2 is like that shown in Fig. 1 but with rounded corners at the edge of the orifice which causes the orifice to resemble that which is found in a common nozzle.
  • the type shown in Fig. 3 resembles the orifice in a common valve where the valve may be opened slightly to produce an orifice in the form of a narrow crac .
  • the area of the orifice may vary, as a practical matter from as small as 0.001 square inches to 1 square inch.
  • the smaller size orifice within this range will require a pressure applied to the mixture of phospholipids and hemoglobin to force it through the orifice of at least 500 pounds per square inch; and with the use of larger orifices, pressures of from 1500 to/ 3000 pounds per square inch are appropriate; and with the use of orifices having an area greater than 0.5 square inch, even greater pressures are appropriate up to the limit of pumping equipment or near 10,000 pounds per square inch.
  • the mixture which passes from vessel 20 through the orifice 25 emerges in the form of hemoglobin ' encapsulated in membranes of the phospholipid composition.
  • hemoglobin ' encapsulated in membranes of the phospholipid composition.
  • These are synthetic erythrocytes which are suspended in hemoglobin solution. They may be retained in receptable 26 and used as a product, or may be subjected to lyophilization at step 27.
  • the material from receptable 26 may also be washed by addition of saline solution, and the washed synthetic erythrocytes centrifuged and filtered at step 28. These may be used as a product, or may be subjected to lyophilization at 29.
  • the washed and filtered synthetic erythrocytes obtained at step 28 may be resuspended in the saline solution to which human albumin is added to form a plasma-like solution at step 37. This may be used as a product, or may be subjected to lyophilization at step 38.
  • the synthetic erythrocytes when formed as a result of our processes as above described, are liquid crystals, but when they are subjected to lyophilization (freeze-drying), their moisture content is diminished. As the moisture content is reduced below 50%, based on the total weight of the synthetic erythrocytes, their structure changes to non-crystalline; and in this state, they are quite stable and have a very slow rate of deterioration. It was not previously known whether reconstitution to the liquid crystal form would be
  • the diluted hemoglobin solution obtained as a by-product of washing the synthetic erythrocytes at step 28, may also be passed to a concentrator 30.
  • the concentrated stroma-free hemoglobin fraction of the solution may be reintroduced along with other stroma-free hemoglobin into vessel 20.
  • the pure saline fraction of the solution may be recirculated back to 10 from which it is recycled again with whole blood.
  • the synthetic erythrocytes formed as a result of our processes typically have a size of from 0.01 to 10 microns at their largest dimension.
  • a vessel 20 which is associated with a source of inert gas such as nitrogen.
  • the nitrogen-, o-r other inert gas is pumped from source 36 into the vessel 20 and much of the gas is absorbed into the mixture of phospholipids and hemoglobin in vessel 20.
  • EXAMPLE 1 In the first part of the process, 40.7 grams of egg lecithin, 20.7 grams of cholesterol, and 6.9 grams of dicetyl phosphate were dissolved in 200 ml of organic solvent consisting of 9 volumes of chloroform nixed with x ⁇ fREA 1 volume of methanol. This solution was poured into a high pressure reactor vessel provided with a stirrer.--:
  • Organic solvent was evaporated by heating the solution at 40°C and by evacuation by means of a vacuum pump, until all solvent was removed, leaving the phospholipid material in the vessel.
  • stroma-free hemoglobin solution was made by freezing and thawing of
  • stroma-free hemoglobin solution 150 ml of stroma-free hemoglobin solution was added to the high pressure reactor vessel containing the phospholipid material made in the first part of the process.
  • the phospholipid material and stroma-free hemoglobin solution was then thoroughly mixed in the vessel.
  • the reactor vessel was then pressurized with- nitrogen-gas, . at 2500 psi, for 15 minutes.
  • the mixture was then expelled, under 2500 psi pressure, through a valve attached to the bottom of the reactor vessel into a receiving vessel. During the passage of the mixture through the valve, pressure was suddenly reduced from
  • EXAMPLE 2 Synthetic erythrocytes, prepared as described in Example 1, were filtered through a filter with 1 micron pores. The resulting filtrate was diluted with the physiologic saline solution in 1:1 ratio by volume, then centrifuged at 4 ⁇ C and 40,000 g for 30 minutes. The supernatant was discarded. The sediment was again diluted with the physiologic saline solution and
  • OMPI centrifugation was repeated.
  • the sediment represented washed synthetic erythrocytes.
  • the washed synthetic ⁇ - erythrocytes were then suspended, in 1:1 volume ratio, in a solution containing 5 gram percent human albumin dissolved in physiologic saline solution. This was synthetic erythrocyte suspension in albumin solution.
  • EXAMPLE 3 200 Grams of synthetic erythrocytes, obtained as in Example 1, were poured into a 1 liter flask. A vacuum pump was attached to the flask and vacuum pumped from the space above the mixture, at 4 ⁇ C, until a sufficient amount of water was evaporated so that the remaining mass could not flow. This was the partially dried, unwashed synthetic erythrocyte suspension.
  • EXAMPLE 4 200 Grams of synthetic erythrocytes, obtained as in Example 1, were poured into a 1 liter flask. A vacuum pump was attached to the flask and vacuum pumped from the space above the mixture, at 4 ⁇ C, until a sufficient amount of water was evaporated so that the remaining mass could not flow. This was the partially dried, unwashed synthetic erythrocyte suspension.
  • Example 3 50 Grams of the partially dried, unwashed synthetic erythrocyte suspension, obtained in Example 3, was subjected to additional drying, at 4 ⁇ C using a vacuum pump, until the mass was dried so that the remaining mass flaked off the sides of the flask. This was the completely dried, unwashed synthetic erythrocyte suspension.
  • EXAMPLE 5 200 Grams of synthetic erythrocytes suspension in albumin solution, obtained in Example 2, was poured into a 1 liter flask. A vacuum pump was attached to the flask and vacuum pumped from the space above the mixture, at 4 ⁇ C, until a sufficient amount of water was evaporated so that the remaining mass could not flow. This was the partially dried, washed synthetic erythrocyte suspension.
  • EXAMPLE 6 50 Grams of the partially dried, washed synthetic erythrocyte suspension, obtained in Example 5, was subjected to additional drying, at 4 ⁇ C using a vacuum pump, until the mass was dried so that the remaining mass flaked off the sides of the flask. This was the completely dried, washed synthetic erythrocyte suspension.
  • EXAMPLE 7 In the first part of the process, 40.7 grams of egg lecithin, 20.7 grams of cholesterol, and 6.9 grams of dicetyl phosphate were dissolved in 200 ml of organic solvent consisting of 9 volumes of chloroform mixed with
  • stroma-free hemoglobin solution was made by freezing , and thawing of
  • stroma-free hemoglobin solution 150 ml of stroma-free hemoglobin solution was added to the high pressure reactor vessel containing the phospholipid material made in the first part of the process.
  • the phospholipid material and stromafree hemoglobin solution were then thoroughly mixed in the vessel.
  • the air was removed from the vessel with a vacuum pump.
  • the reactor vessel was then pressurized with the piston to 2500 psi pressure.
  • the mixture was expelled, under 2500 psi pressure, through a valve attached to the bottom of the reactor vessel into a receiving vessel. During the passage through the valve, the mixture was extruded producing spheroid particles, of approximately 0.5 microns in diameter, densely suspended in the stroma-free hemoglobin solution. These particles represented synthetic erythrocytes.
  • EXAMPLE 10 50 Grams -of the partially dried, unwashed synthetic erythrocyte suspension, obtained in Example 9, was subjected to additional drying, at 4 ⁇ C using a vacuum pump, until the mass was dried so that the remaining mass flaked off the sides of the flask. This was the completely dried, unwashed synthetic erythrocyte suspension.
  • EXAMPLE 11 200 Grams of synthetic erythrocytes, obtained in Example 8, were poured into a 1 liter flask. A vacuum pump was attached to the flask and vacuum pumped from the space above the mixture, at 4 ⁇ C, until a sufficient amount of water was evaporated so that the remaining mass could not flow. This was the partially dried, washed synthetic erythrocyte suspension.
  • EXAMPLE 12 50 Grams of the partially dried, unwashed synthetic erythrocyte suspension, obtained in Example 11, was subjected to additional drying, at 4°C using a vacuum pump, until the mass was dried so that the remaining mass flaked off the sides of the flask. This was the completely dried, washed synthetic erythrocyte suspension.
  • EXAMPLE 13 40 Ml of synthetic erythrocyte suspension in albumin solution, obtained in Example 2, containing 50% synthetic erythrocytes by volume was administered to a rat by a technique wherein an infusion pump was employed to effect simultaneous withdrawal of blood fron the femoral artery and infusion of the synthetic erythrocyte suspension into the-femoral vein. All 40 ml of suspension (approximately 250% of the rat's natural blood volume) was administered over a period of 3 hours. The rat survived the transfusion for more than 24 hours and eventually died of bacterial infection (septic shock ⁇ .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La préparation d'érythrocytes synthétiques consiste à former un mélange de phospholipide et d'hémoglobine exempte de stroma et à faire passer ce mélange sous une pression comprise en 500 et 10000 livres par pouce carré au travers d'un orifice de manière à former des érythrocytes synthétiques qui contiennent de l'hémoglobine exempte de stroma dans des membranes du matériau de phospholipide. Cela consiste aussi à soumettre les érythrocytes synthétiques ainsi formés à un procédé de lyophilisation pour convertir la structure de cristaux liquides des érythrocytes en un liquide non cristallin capable de se reconstituer dans sa forme de cristaux liquides. Cela comprend aussi la recirculation de l'hémoglobine exempte de stroma non encapsulée dans des membranes de phospholipide à introduire de nouveau ensemble avec une autre hémoglobine exempte de stroma mélangée à des lipides.
EP82902427A 1981-07-06 1982-07-06 Preparation d'erythrocytes synthetiques Withdrawn EP0082877A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28044181A 1981-07-06 1981-07-06
US280441 1994-07-25

Publications (1)

Publication Number Publication Date
EP0082877A1 true EP0082877A1 (fr) 1983-07-06

Family

ID=23073112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82902427A Withdrawn EP0082877A1 (fr) 1981-07-06 1982-07-06 Preparation d'erythrocytes synthetiques

Country Status (2)

Country Link
EP (1) EP0082877A1 (fr)
WO (1) WO1983000089A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4662891A (en) * 1983-11-21 1987-05-05 Joint Medical Products Corporation Fixation elements for artificial joints
GB8407557D0 (en) * 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US4911929A (en) * 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
JPH02121931A (ja) * 1988-10-29 1990-05-09 Res Inst For Prod Dev 濃縮ヘモグロビンの製造方法
DE19542499A1 (de) * 1995-11-15 1997-05-22 Bayer Ag Verfahren und Vorrichtung zur Herstellung einer parenteralen Arzneistoffzubereitung
HUP0101713A2 (hu) * 2001-04-27 2003-02-28 István Horváth Eljárás mesterséges vér előállítására liofilezett vagy friss vérből nyerhető hemoglobin felhasználásával

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4192869A (en) * 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8300089A1 *

Also Published As

Publication number Publication date
WO1983000089A1 (fr) 1983-01-20

Similar Documents

Publication Publication Date Title
US4133874A (en) Lipid encapsulated hemoglobin cells
US4532130A (en) Preparation of synthetic frythrocytes
US4963526A (en) Oral insulin and a method of making the same
US4849405A (en) Oral insulin and a method of making the same
US4423077A (en) Perfluorochemical emulsion artificial blood
US4425334A (en) Functional oxygen transport system
AU614173B2 (en) Hemoglobin multiple emulsion
US4478824A (en) Method for altering red blood cell function and survival
EP0101341A1 (fr) Procédé et dispositif pour l'encapsulation dans les érythrocytes d'au moins une substance à activité biologique, notamment des effecteurs allostériques de l'hémoglobine et érythrocytes ainsi obtenus
US4343797A (en) Synthetic whole blood and a method of making the same
US4439424A (en) Synthetic whole blood
US4547490A (en) Synthetic whole blood and a method of making the same
US4497829A (en) Process for preparing perfluorochemical emulsion artificial blood
WO1983000089A1 (fr) Preparation d'erythrocytes synthetiques
EP0124527B1 (fr) Sang entier synthetique a base de gelatine et son procede de fabrication
Chae et al. Effect of cross-linked hemoglobin on functionality and viability of microencapsulated pancreatic islets
CN113769118A (zh) 一种血小板膜仿生超声微泡及其制备方法、用途
EP0001104B1 (fr) Erythrocytes intacts modifiés, sang ou conserves de sang les contenant et procédé pour leur préparation
JPS58502204A (ja) 合成全血およびその製造方法
US4612370A (en) Lipid-saccharide reaction products
Borwanker et al. Formulation and characterization of a multiple emulsion for use as a red blood cell substitute
JPH07500597A (ja) 移植用細胞の冷凍方法
AU680828B2 (en) Islets of Langerhan's in pure form
JP2999815B2 (ja) 人工血液
JPH045242A (ja) 人工血液

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19830905

RIN1 Information on inventor provided before grant (corrected)

Inventor name: IVANKOVICH, ANTHONY DRAGAN

Inventor name: GOTTSCHALK, WILLIAM

Inventor name: DJORDJEVICH, LJUBOMIR